Study treatment schema and patient disposition flowchart. (A) The study treatment schema. Treatment consisted of romidepsin 10 mg/m² (with dose escalation to 14 mg/m² as tolerated) IV on days 1, 8, and 15 and lenalidomide 25 mg taken orally from days 1 to 21 of 28-day cycle for up to 1 year. (B) The flowchart for patient disposition. Of the 29 patients enrolled, 20 completed at least 3 cycles of study treatment and were evaluable. Fifteen participants achieved responses.